Geneva Advisors’s BioTelemetry, Inc. BEAT Stock Holding History

Geneva Advisors’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-23,077	Closed	-$668K	–	819
2017 Q1	$668K	Buy	+23,077	New	+$572K	0.01%	436

Other funds holding BEAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Geneva Advisors's BEAT Position: Q2 2017 in Review

Geneva Advisors sold out of BioTelemetry, Inc. (BEAT) in Q2 2017, closing a stake of 23,077 shares — an estimated $668K sold.

Geneva Advisors first reported a position in BEAT in Q1 2017 and held it in 1 quarter. The position peaked at $668K in Q1 2017. 195 funds tracked by Wall St. Rank hold BEAT as of Q2 2017.

Geneva Advisors reported no remaining BioTelemetry, Inc. position as of Q2 2017 after selling out during the quarter.
Geneva Advisors sold 23,077 BioTelemetry, Inc. shares in Q2 2017, an estimated $668K.
Geneva Advisors first reported a position in BioTelemetry, Inc. in Q1 2017 and held it in 1 quarter.
Geneva Advisors's BioTelemetry, Inc. position peaked at $668K in Q1 2017.
195 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.